H1N1 (swine flu) & the R&D-based Pharmaceutical Industry
The R&D-based Pharmaceutical Industry’s response to the H1N1 influenza pandemic.
The R&D-based Pharmaceutical Industry’s response to the H1N1 influenza pandemic.
On 7 June 2023, IFPMA hosted a unique opportunity to hear from 10 companies, about the different partnership models that supported the industry’s response to COVID-19. This open event included discussion on the challenges of scaling up manufacturing to meet global demand for vaccines and treatments, with representatives from MSD – Dr Reddy’s Laboratories; Gilead...
Read moreOn 4 June, IFPMA delivered a statement on Priority I “Health Emergencies Prevention, Preparedness, and Response” at the G20 3rd Health Working Group Meeting in Hyderabad.
Read moreOn 4 June, IFPMA delivered a statement on Priority II “Strengthening cooperation in pharmaceutical sector with focus on availability and access to safe, effective, quality, and affordable medical countermeasures (MCM) – VTDs (vaccines, therapeutics, and diagnostics)” at the G20 3rd Health Working Group Meeting in Hyderabad.
Read more